# EDGAR Filing Document

**Accession Number:** 0001178670
**File Stem:** 0001628280-26-007687
**Filing Date:** 2026-2
**Character Count:** 18694
**Document Hash:** 052d66ef593c25e70c3a8965aa6bac53
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-007687.hdr.sgml**: 20260212

**ACCESSION NUMBER**: 0001628280-26-007687

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260212

**DATE AS OF CHANGE**: 20260212

**EFFECTIVENESS DATE**: 20260212

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALNYLAM PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001178670
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 770602661
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293419
- **FILM NUMBER:** 26626421

**BUSINESS ADDRESS:**
- **STREET 1:** 675 WEST KENDALL STREET
- **STREET 2:** HENRI A. TERMEER SQUARE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** (617) 551-8200

**MAIL ADDRESS:**
- **STREET 1:** 675 WEST KENDALL STREET
- **STREET 2:** HENRI A. TERMEER SQUARE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALNYLAM PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20020724

**As filed with the Securities and Exchange Commission on February 12, 2026**

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

**Alnylam Pharmaceuticals, Inc.**

**(Exact name of registrant as specified in its charter)** 

<u><br></u>

---

| | |
|:---|:---|
| **Delaware** | **77-0602661** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

**675 West Kendall Street, Henri A. Termeer Square**

**Cambridge, Massachusetts 02142**

**(Address of principal executive offices, including zip code)**

**Second Amended and Restated 2018 Stock Incentive Plan**

**(Full title of the plan)** 

**Yvonne L. Greenstreet, M.D.** 

**Chief Executive Officer** 

**Alnylam Pharmaceuticals, Inc.** 

**675 West Kendall Street,** 

**Henri A. Termeer Square** 

**Cambridge, Massachusetts 02142**

**(Name and address of agent for service)** 

**(617) 551-8200**

**(Telephone number, including area code, of agent for service)** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ | | |

---

If an emerging growth company indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

<u><br></u>

------

**EXPLANATORY NOTE** 

On February 27, 2025, the board of directors (the "Board") of Alnylam Pharmaceuticals, Inc. (the "Registrant") approved a second amendment and restatement of the Registrant's 2018 Stock Incentive Plan, as amended. The 2018 Stock Incentive Plan, as previously amended and restated, is referred to herein as the "2018 Plan," and the second amendment and restatement of the 2018 Plan is referred to herein as the "Second Amended Plan." Pursuant to the Second Amended Plan, the number of shares of common stock, par value $0.01 per share ("Common Stock") reserved and available for issuance under the 2018 Plan was increased by 7,000,000 shares, subject to stockholder approval, which was received on May 8, 2025. This Registration Statement on Form S-8 registers these 7,000,000 additional shares of Common Stock. The additional shares available for issuance under the Second Amended Plan are of the same class as other securities relating to the 2018 Plan for which the Registrant's registration statements filed on Form S-8 (Registration No. 333-226533) on <u>[August 2, 2018](https://www.sec.gov/Archives/edgar/data/1178670/000119312518236768/d591157ds8.htm)</u>, on Form S-8 (Registration No. 333-236409) on <u>[February 13, 2020](https://www.sec.gov/Archives/edgar/data/1178670/000119312520034390/d868105ds8.htm)</u>, on Form S-8 (Registration No. 333-252994) on <u>[February 11, 2021](https://www.sec.gov/Archives/edgar/data/1178670/000119312521038563/d114010ds8.htm)</u>, and on Form S-8 (Registration No. 333-269939) on <u>[February 23, 2023](https://www.sec.gov/Archives/edgar/data/1178670/000119312523046503/d460009ds8.htm)</u>, are effective.

The information contained in the Registrant's prior registration statements on Form S-8 referenced above is hereby incorporated by reference pursuant to General Instruction E, except for "Item 6. Indemnification of Directors and Officers" and "Item 8. Exhibits."

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 6. Indemnification of Directors and Officers.**

Section 145 of the General Corporation Law of the State of Delaware (the "DGCL") provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney's fees) against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

Section 102(b)(7) of the DGCL provides, generally, that the certificate of incorporation of a corporation may contain a provision eliminating or limiting the personal liability of a director or an officer to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision may not eliminate or limit the liability of a director or an officer (i) for any breach of the director's or officer's duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DCGL, or (iv) for any transaction from which the director or officer derived an improper personal benefit, and provided further that such provision shall not eliminate or limit the liability of an officer in any action by or in the right of the corporation. No such provision may eliminate or limit the liability of a director for any act or omission occurring prior to the date when such provision became effective.

------

The Registrant's Restated Certificate of Incorporation, as amended by the Certificate of Amendment filed with the Secretary of State of the State of Delaware on May 8, 2025 (the "Amended Charter"), provides that no director or officer of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director or an officer, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors or officers, as applicable, for breaches of fiduciary duty. In addition, the Amended Charter provides that if the DGCL is amended to authorize the further elimination or limitation of the liability of directors or officers, then the liability of a director or officer of the Registrant shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.

The Registrant has entered into indemnification agreements with its directors and certain of its officers, in addition to the indemnification provided for in its Amended Certificate, and intends to enter into indemnification agreements with any new directors and certain officers in the future. The Registrant has have purchased and intends to maintain insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

**Item 8. Exhibits.** 

---

| | |
|:---|:---|
| Exhibit | Description |
| 5.1\* | <u>[Opinion of Ropes & Gray, LLP, counsel to the Registrant.](alny2026exhibit51.htm)</u> |
| 23.1\* | <u>[Consent of Ropes & Gray LLP, counsel to the Registrant (included in Exhibit 5.1).](alny2026exhibit51.htm)</u> |
| 23.2\* | <u>[Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.](alny2026exhibit232.htm)</u> |
| 24.1\* | <u>[Powers of Attorney (included on the signature page of this registration statement).](#i57e85e2b50684eef9cad2184de334f30_89)</u> |
| 99.1 | <u>[Second Amended and Restated 2018 Stock Incentive Plan (filed as Exhibit 10.8 to the Registrant's Annual Report on Form 10-K filed on February 12, 2026 (File No. 001-36407) for the year ended December 31, 2025 and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny2025q4exhibit108.htm)</u> |
| 107.1\* | <u>[Filing Fee Table.](exfilingfees.htm)</u> |

---

**\*&nbsp;&nbsp;&nbsp;&nbsp;**Filed herewith.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 12<sup>th</sup> day of February, 2026.

---

| | |
|:---|:---|
| **ALNYLAM PHARMACEUTICALS, INC.** | **ALNYLAM PHARMACEUTICALS, INC.** |
| By: | /s/ Yvonne L. Greenstreet |
|  | Yvonne L. Greenstreet, M.D. |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY AND SIGNATURES**

We, the undersigned officers and directors of Alnylam Pharmaceuticals, Inc., hereby severally constitute and appoint Yvonne L. Greenstreet, M.D. and Jeffrey V. Poulton, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Alnylam Pharmaceuticals, Inc. to comply with the provisions of the Securities Act of 1933, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Yvonne L. Greenstreet | Chief Executive Officer and Director | February 12, 2026 |
| Yvonne L. Greenstreet, M.D. | (Principal Executive Officer) |  |
| /s/ Jeffrey V. Poulton | Executive Vice President and Chief Financial Officer | February 12, 2026 |
| Jeffrey V. Poulton | (Principal Financial Officer and Accounting Officer) |  |
| /s/ Stuart A. Arbuckle | Director | February 12, 2026 |
| Stuart A. Arbuckle |  |  |
| /s/ Dennis A. Ausiello | Director | February 12, 2026 |
| Dennis A. Ausiello, M.D |  |  |
| /s/ Olivier Brandicourt | Director | February 12, 2026 |
| Olivier Brandicourt, M.D. |  |  |
| /s/ Margaret A. Hamburg | Director | February 12, 2026 |
| Margaret A. Hamburg, M.D. |  |  |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Peter N. Kellogg | Director | February 12, 2026 |
| Peter N. Kellogg |  |  |
| /s/ David E.I. Pyott | Director | February 12, 2026 |
| David E.I. Pyott |  |  |
| /s/ Colleen F. Reitan | Director | February 12, 2026 |
| Colleen F. Reitan |  |  |
| /s/ Amy W. Schulman | Director | February 12, 2026 |
| Amy W. Schulman |  |  |
| /s/ Elliott Sigal | Director | February 12, 2026 |
| Elliott Sigal, M.D., Ph.D. |  |  |

---

## Exhibit 5.1

![ropesa.jpg](ropesa.jpg)

**Exhibit 5.1**

ROPES & GRAY LLPPRUDENTIAL TOWER800 BOYLSTON STREETBOSTON, MA 02199-3600WWW.ROPESGRAY.COM

February 12, 2026

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street,

Henri A. Termeer Square

Cambridge, Massachusetts 02142

Ladies and Gentlemen:

This opinion letter is furnished to you in connection with the registration statement on Form S-8 (the "<u>Registration Statement</u>"), filed by Alnylam Pharmaceuticals, Inc., a Delaware corporation (the "<u>Company</u>"), on the date hereof, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), for the registration of 7,000,000 shares of Common Stock, par value $0.01 per share (the "<u>Shares</u>"), of the Company. The Shares are issuable under the Company's Second Amended and Restated 2018 Stock Incentive Plan (the "<u>Plan</u>").

We are familiar with the actions taken by the Company in connection with the adoption of the Plan. We have examined and relied upon such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons.

The opinions expressed below are limited to the Delaware General Corporation Law.

Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued and sold in accordance with the terms of the Plan, the Shares will be validly issued, fully paid and non-assessable.

We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

------

&nbsp;&nbsp;&nbsp;&nbsp;- 2 -

&nbsp;&nbsp;&nbsp;&nbsp;

Very truly yours,

/s/ Ropes & Gray LLP

Ropes & Gray LLP

## Exhibit 23.2

**Exhibit 23.2**

<u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Alnylam Pharmaceuticals, Inc. of our report dated February 12, 2026 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Alnylam Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

February 12, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**Exhibit 107.1** 

**Table 1. Newly Registered Securities** 

**CALCULATION OF REGISTRATION FEE** 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| Security Type | Security<br>Class<br>Title | Fee<br>Calculation<br>Rule | Amount<br>Registered(1) | Proposed<br>Maximum<br>Offering<br>Price per<br>Share(2) | Maximum<br>Aggregate<br>Offering<br>Price | Fee<br>Rate | Amount of<br>Registration<br>Fee |
| Equity | Common Stock, $0.01<br>par value per share | Other(2) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7,000,000 shares(3) | $321.94 | $2253580000 | $0.0001381 | $311219.40 |
| Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts |  | $2253580000 |  | $311219.40 |
| Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  | $0 |
| Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  | $311219.40 |

---

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock which become issuable under the Registrant's Second Amended and Restated 2018 Stock Incentive Plan (the "Amended Plan") by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number outstanding shares of the Registrant's common stock.

(2) Estimated in accordance with Rule 457(c) and Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $321.94 per share, which is the average of the high and low prices of the common stock on February 10, 2026, as reported on the Nasdaq Global Select Market.

(3) Represents 7,000,000 shares of common stock that were added to the shares authorized for issuance under the Amended Plan, pursuant to the approval of the Amended Plan approved by the Registrant's board of directors (the "Board") on February 27, 2025 and its stockholders on May 8, 2025.

167427502_2